ORGANOIDSCIENCES
Organoidsciences Ltd. develops regenerative therapies in South Korea. It develops ATORM, an adult tissue derived organoid based regenerative medicine platform for the treatment of intractable intestinal ulcers, as well as salivary glands, liver, and uterus disease areas; ODISEI solutions, an organoid-based discovery platform for screening evaluation and identification; and EXPANSION, an organoid-… Read more
ORGANOIDSCIENCES (476040) - Net Assets
Latest net assets as of December 2024: ₩15.31 Billion KRW
Based on the latest financial reports, ORGANOIDSCIENCES (476040) has net assets worth ₩15.31 Billion KRW as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩25.89 Billion) and total liabilities (₩10.58 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩15.31 Billion |
| % of Total Assets | 59.14% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ORGANOIDSCIENCES - Net Assets Trend (2021–2024)
This chart illustrates how ORGANOIDSCIENCES's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ORGANOIDSCIENCES (2021–2024)
The table below shows the annual net assets of ORGANOIDSCIENCES from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩15.31 Billion | +119.80% |
| 2023-12-31 | ₩-77.34 Billion | -95.49% |
| 2022-12-31 | ₩-39.56 Billion | -147.84% |
| 2021-12-31 | ₩-15.96 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to ORGANOIDSCIENCES's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7406492203000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩2.63 Billion | 17.21% |
| Other Components | ₩104.34 Billion | 681.41% |
| Total Equity | ₩15.31 Billion | 100.00% |
ORGANOIDSCIENCES Competitors by Market Cap
The table below lists competitors of ORGANOIDSCIENCES ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SHIONOGI & CO LTD - Dusseldorf Stock Exchang
DU:SH0
|
$176.55K |
|
PortfolioMan AI Alpha Lab Glob Akt kl n
CO:PMIAAN
|
$176.58K |
|
Keramika Indonesia Assosiasi
JK:KIAS
|
$176.71K |
|
SOZAP AB
F:9RI
|
$176.74K |
|
FUJI HEAVY IND
BE:FUH
|
$176.39K |
|
DDTN
BATS:DDTN
|
$176.31K |
|
Nykredit Invest Bæredygtige Aktier
CO:NYIBDA
|
$176.28K |
|
SparDanmark Invest Vækst
CO:SDIVKS
|
$176.27K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ORGANOIDSCIENCES's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -77,337,777,670 to 15,312,547,750, a change of 92,650,325,420.
- Net loss of 11,246,456,470 reduced equity.
- New share issuances of 200,001,000 increased equity.
- Other factors increased equity by 103,696,780,890.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-11.25 Billion | -73.45% |
| Share Issuances | ₩200.00 Million | +1.31% |
| Other Changes | ₩103.70 Billion | +677.2% |
| Total Change | ₩- | % |
Book Value vs Market Value Analysis
This analysis compares ORGANOIDSCIENCES's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 11.34x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | ₩-2453.48 | ₩26700.00 | x |
| 2022-12-31 | ₩-6080.62 | ₩26700.00 | x |
| 2023-12-31 | ₩-11887.24 | ₩26700.00 | x |
| 2024-12-31 | ₩2353.62 | ₩26700.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ORGANOIDSCIENCES utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -73.45%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -575.78%
- • Asset Turnover: 0.08x
- • Equity Multiplier: 1.69x
- Recent ROE (-73.45%) is below the historical average (-18.36%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | -6518.04% | 0.01x | 0.00x | ₩-16.02 Billion |
| 2022 | 0.00% | -5501.84% | 0.01x | 0.00x | ₩-20.16 Billion |
| 2023 | 0.00% | -2431.56% | 0.05x | 0.00x | ₩-30.95 Billion |
| 2024 | -73.45% | -575.78% | 0.08x | 1.69x | ₩-12.78 Billion |
Industry Comparison
This section compares ORGANOIDSCIENCES's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ORGANOIDSCIENCES (476040) | ₩15.31 Billion | 0.00% | 0.69x | $176.41K |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |